ʻO ka ZILBRYSQ Autoinjector ka ʻae ʻana a me ka mākaukau lawe peptide: He aha ka 2026 Nā Hoʻololi ʻApono no kāu Polokalamu

Pane wikiwiki

UCB's October 2026 FDA approval of a ZILBRYSQ autoinjector adds a second self-administration option alongside the existing prefilled syringe, with commercial a…

He aha ka FDA i apono maoli ai no ZILBRYSQ, a he aha nā hōʻike i kākoʻo i ka autoinjector?

ʻIkepili Peptide Hexarelin Peptide Ua kau ka ʻae ʻia ma nā ʻano haʻawina ʻekolu, a pane kēlā me kēia i kahi nīnau ʻokoʻa. ʻO ka ʻikepili hoʻohana Phase 3b i ka hōʻike hoʻolaha hoʻolaha o ka UCB i ka hāʻawi ʻana i ka nui no 99.8% (n=449) o na hooponopono autoinjector, kahi o ka denominator ka huina autoinjector i hoʻohana ʻia a hoʻihoʻi ʻia, ʻaʻole nā ​​maʻi (ʻO ka hoʻolaha ʻana o ka UCB).

ʻO ka ZILBRYSQ Autoinjector ka ʻae ʻana a me ka mākaukau lawe peptide: He aha ka 2026 Nā Hoʻololi ʻApono no kāu Polokalamu

Ua hoʻopaʻa inoa ʻia ka haʻawina hōʻoia kanaka 100 nā mea komo ma waena o nā maʻi, nā mea mālama a me nā limahana mālama ola kino, a 90% hoʻopau i kahi injection ma ka hoʻāʻo mua ʻana me ke aʻo ʻole (ʻO ka hoʻolaha ʻana o ka UCB). ʻO ka haʻawina bioequivalence i wehewehe ʻia ma ka hoʻokuʻu, DV0012, he lua-manawa crossover in 14 kanaka makua olakino; ua hoʻokumu ʻia ka bioequivalence akā ʻaʻole i hoʻopuka i nā ratio AUC a i ʻole Cmax.

ʻO ka mea ʻaʻole pili i ka lehulehu: nā mea pani pani o ka autoinjector, ʻO kāna pūʻolo mea hiki ke unuhi a me ka leachable, a ʻaʻole i loaʻa ka ʻikepili kūpaʻa pani o ka pahu mai ka hoʻokuʻu ʻana a me ka lepili.

ʻO ka ZILBRYSQ Autoinjector ka ʻae ʻana a me ka mākaukau lawe peptide: He aha ka 2026 Nā Hoʻololi ʻApono no kāu Polokalamu

Ki Takeaway Hoʻohui ʻia kahi mea hoʻohui i kahi koho hoʻokele ma ka mole like a me ka hōʻailona. Hoʻololi ka hoʻololi ʻana i ka huahana lāʻau ponoʻī. Lawe nā mea ʻelua i nā kaumaha hōʻike like ʻole, a ʻo ka lua wale nō e wehe hou i ka ʻōlelo kikoʻī lāʻau.

No ke aha i lawa ʻole ai kahi kaʻina i hoʻopaʻa ʻia a me nā kikoʻī maʻemaʻe e hoʻomaka ai i kahi peptide i hāʻawi ʻia e nā mea hana?

ʻO ka mākaukau hāʻawi peptide kahi waiwai o ka huahana lāʻau i loko o kāna pahu a me kāna mea hana, ʻaʻole o ka palapala hōʻoia mea lāʻau. ʻO kahi kikoʻī he mana haiki e ka hoʻolālā. I Q6B wehewehe Peptide kanaka he papa inoa o na hoao ana, nā kaʻina hana analytical a me ka ʻae ʻana i manaʻo ʻia e ka mea hana. Hōʻoia i ka maikaʻi; ʻaʻole ia e hoʻokumu i ke ʻano piha. USP <1503> hāʻawi i nā peptides synthetic i ke ʻano like: helehelena, ʻike ma o nā ʻenehana orthogonal, hōʻike, haumia a me nā hoʻokolohua kikoʻī.

ʻAʻohe o ia mea e wehewehe ana i ke ʻano o ka hana ʻana o ka mole ke hoʻokuʻu ʻia e kahi pūnāwai i loko o kahi nila 29-gauge.. ʻO ka FDA Hale Hana Huahana Peptide 2026 kiʻi i nā inoa alakaʻi pani-pani ʻana i nā syringes piston ma waena o nā ʻōnaehana pani ipu i ʻāpana pū kekahi. Manaʻo ia i ka ikaika holo, ka hoʻāʻo ʻana i ka ʻoiaʻiʻo a me ka hoʻāʻo ʻana i ka ʻoiaʻiʻo.

Loaʻa i ka huahana kekahi mau kiko piha a me nā ikaika. E hōʻoia i ka hōʻike ʻana i ʻāpono ʻia a me ka hoʻonohonoho ʻana o ka mea hana no kēlā me kēia; ʻAʻole hōʻike nā puke like ʻole e hiki i kahi mea hoʻololi hoʻololi ke mālama i kēlā me kēia hōʻike.

ʻO ka mālama ʻana i nā hōʻike mea hana ma ke ʻano he koho he kumu kūʻai palapala. Nā leka pane piha a FDA no Remodulin e ʻōlelo " lawa nā kumu kanaka (HF) ʻAʻole i hāʻawi ʻia ka ʻikepili e hōʻike i ke kākoʻo o ka mea hoʻohana i ka hoʻohana palekana a maikaʻi hoʻi.

Pehea ka noonoo ana, ka nui dose, ʻO ka viscosity a me ka hoʻopili pahu e hoʻoholo inā hiki ke hoʻohālikelike ʻia kahi hāmeʻa?

Pili ka hana ʻana o ka hāmeʻa i ka leo, viscosity, ʻōniʻoniʻo kui, ikaika, ka mahana a me ka hoʻokumu pū ʻana. ʻAʻole hiki i nā laʻana e hoʻohana ana i nā nila like ʻole ke hoʻokaʻawale i ka hopena o ka viscosity. E hoʻonoho i nā koi me ka hoʻohana ʻana i ka maʻamau a me ka hoʻonohonoho pono ʻana ma mua o ka leo ākea a i ʻole 10 N palena. Antimicrobial Peptides

<papa helu ="blog-chart" kaila="laula-nui:640px;palena palena:1.5rem auto;nui-momona:12px;kiʻekiʻe laina:1.3;kala kala:hooilina"> <svg viewBox="0 0 560 380" kaila="laula-nui: 100%; kiekie: kaʻa; font-ohana: 'Inter', ʻōnaehana-ui, sans-serif; kala kala: #1e293b; --pakuhi-muted: #64748b;" kuleana="img" aria-labelledby="zilbrysq-dose-volume-e-kaumaha-band-title zilbrysq-dos-nui-ma-kaumaha-band-desc"> <kaila> /* Hoʻokomo ka mea hāʻawi i ka pakuhi i loko o kahi iframe nona ka ʻeleʻele ʻeleʻele, a he ʻano ʻokoʻa ka iframe i ka pakuhi, no laila ua hōʻike ʻia nā pahu pahu leka me he mau papa ʻeleʻele a puni (prod 09-22). Akaka ka palapala i loko o ka iframe ma ka paʻamau; ʻO ka pena kiʻi ma ʻaneʻi e uhi ana i ke kāʻei o ka element, a ke kau ʻia ka pakuhi, ʻaʻohe mea pili kēia. E mālama i nā pale kihi ma waho o kēia poloka: ʻO kahi mea ʻano i loko o kahi SVG i hoʻokaʻawale ʻia ma ke ʻano he ʻike haole, no laila, hoʻolei kekahi bracket hele i kēlā me kēia lula i loko. */ html, kino { hope: #ffffff; palena palena: 0; } @media (makemake-hoemi-holo: hoemi) { * { hoʻouluulu: ʻaʻohe !mea nui; hoʻololi: ʻaʻohe !mea nui; } } </kaila> <pololei x="0" y="0" laula="560" kiekie="380" rx="8" hoʻopiha="#ffffff" /> <inoa id="zilbrysq-dose-volume-by-weight-band-title">ʻO ZILBRYSQ ka nui o ka hoʻopaʻa ʻana ma ke kāʻei kaumaha</inoa> <wehewehe id="zilbrysq-dose-volume-by-weight-band-desc">Hāʻawi nā ikaika ʻekolu i ʻae ʻia 0.416, 0.574 a 0.81 mL no hoʻokahi maʻi subcutaneous i kēlā me kēia lā. ʻO ZILBRYSQ ka nui o ka hoʻopaʻa ʻana ma ke kāʻei kaumaha. ʻikepili pae pae: <56 kg 0.416; 56 i <77 kg 0.574; ≥77 kg 0.81.Kumu: ZILBRYSQ e kuhikuhi ana i ka ʻike 2023.</wehewehe> <kikokikona x="280.0" y="29" heleuma kikokikona="waena" font-size="18" font-kaumaha="800" hoʻopiha="kala kala">ʻO ZILBRYSQ ka nui o ka hoʻopaʻa ʻana ma ke kāʻei kaumaha</kikokikona> <laina x1="145" y1="298.0" x2="510" y2="298.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="243.0" x2="510" y2="243.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="188.0" x2="510" y2="188.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="133.0" x2="510" y2="133.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="78.0" x2="510" y2="78.0" hahau ="kala kala" opacity="0.08" /> <kikokikona x="136.0" y="122.2" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0"><56 kg</tspan></kikokikona> <pololei x="145" y="78.0" laula="151.8" kiekie="68.0" rx="4" hoʻopiha="#f97316" /> <kikokikona x="304.8" y="122.2" font-size="11" hoʻopiha="kala kala">0.416</kikokikona> <kikokikona x="136.0" y="198.2" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">56 i <77 kg</tspan></kikokikona> <pololei x="145" y="154.0" laula="209.5" kiekie="68.0" rx="4" hoʻopiha="#38bdf8" /> <kikokikona x="362.5" y="198.2" font-size="11" hoʻopiha="kala kala">0.574</kikokikona> <kikokikona x="136.0" y="274.2" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">≥77 kg</tspan></kikokikona> <pololei x="145" y="230.0" laula="295.7" kiekie="68.0" rx="4" hoʻopiha="#a78bfa" /> <kikokikona x="448.7" y="274.2" font-size="11" hoʻopiha="kala kala">0.81</kikokikona> <kikokikona x="280.0" y="366" heleuma kikokikona="waena" font-size="10" hoʻopiha="kā mākou(--pakuhi-muted, kala kala)">Puna: ZILBRYSQ e kuhikuhi ana i ka ʻike (2023)</kikokikona> </svg> </huahelu>

ʻO ka pilina pahu kahi i kū ai ka palapala peptide. I ka epoetin alfa prefilled-syringe hihia, ʻelua pūʻulu i hoʻopiha ʻia mai ka hoʻonā like ʻokoʻa i ka leo hoʻopiha wale nō, a me nā syringe pākahi i hōʻuluʻulu ʻia a hiki i 5.1% a 1.5%, me ka soluble tungsten averaging a puni 1 ppm a hiki aku 4 ppm i nā syringes pākahi (Seidl et al. i ka noiʻi lāʻau lapaʻau). Ua paʻi ʻia nā ʻikepili ua tungsten i ka neʻe ʻana o ka paepae mai kahi 3 ppm ma ka pH 5.0 ʻaʻohe ua i luna 200 ppm ma ka pH 6.0 (ʻO Bee et al. ma ka Journal of Pharmaceutical Sciences). ʻO ka ʻaila silikoni a me ka tungsten nā mea lawe pahu, ʻaʻole nā ​​ʻano peptide, no laila ʻaʻole hiki ke hōʻoia ʻia ka hoʻopili ʻana o ka pahu peptide e ka mea hoʻolako waiwai.

Loaʻa i nā mea unuhi a me nā leachable ko lākou ʻano ponoʻī a me nā paepae. USP <1663> a <1664> hoʻonohonoho i ke ʻano loiloi, ʻoiai ʻo ka PQRI parenteral E&L wahi paepae a 1.5 µg/lā ka paepae pilikia palekana a 5 µg/lā ka paepae hōʻoia no kēlā me kēia kanaka hoʻoheheʻe organik (USP; PQRI). ʻO ke kumu kuhikuhi ICH Q3E, ma Step 2 mai ʻAukake 2025, hoʻonui i ka laulā i nā huahana hui lāʻau me ka hoʻokō i manaʻo ʻia e Iune 2027 (I Q3E ʻanuʻu 2 hoikeike).

He aha kaʻu e koi ai mai kaʻu hoa peptide me kaʻu hoa hana ma mua o ka laka ʻana i kahi ʻano?

Laka i kahi ʻano mea hana ma hope wale nō o ka pūʻolo lāʻau, ua loiloi pū ʻia nā hiʻohiʻona o ka hoʻokumu ʻana a me ka ʻaoʻao o ka pahu. ʻO ia ka mea e hoʻoholo ai i ka mākaukau lawe peptide, ʻaʻole he lima lima.

<papa helu ="blog-chart" kaila="laula-nui:640px;palena palena:1.5rem auto;nui-momona:12px;kiʻekiʻe laina:1.3;kala kala:hooilina"> <svg viewBox="0 0 560 380" kaila="laula-nui: 100%; kiekie: kaʻa; font-ohana: 'Inter', ʻōnaehana-ui, sans-serif; kala kala: #1e293b; --pakuhi-muted: #64748b;" kuleana="img" aria-labelledby="parenteral-leachable-thresholds-title parenteral-leachable-thresholds-desc"> <kaila> /* Hoʻokomo ka mea hāʻawi i ka pakuhi i loko o kahi iframe nona ka ʻeleʻele ʻeleʻele, a he ʻano ʻokoʻa ka iframe i ka pakuhi, no laila ua hōʻike ʻia nā pahu pahu leka me he mau papa ʻeleʻele a puni (prod 09-22). Akaka ka palapala i loko o ka iframe ma ka paʻamau; ʻO ka pena kiʻi ma ʻaneʻi e uhi ana i ke kāʻei o ka element, a ke kau ʻia ka pakuhi, ʻaʻohe mea pili kēia. E mālama i nā pale kihi ma waho o kēia poloka: ʻO kahi mea ʻano i loko o kahi SVG i hoʻokaʻawale ʻia ma ke ʻano he ʻike haole, no laila, hoʻolei kekahi bracket hele i kēlā me kēia lula i loko. */ html, kino { hope: #ffffff; palena palena: 0; } @media (makemake-hoemi-holo: hoemi) { * { hoʻouluulu: ʻaʻohe !mea nui; hoʻololi: ʻaʻohe !mea nui; } } </kaila> <pololei x="0" y="0" laula="560" kiekie="380" rx="8" hoʻopiha="#ffffff" /> <inoa id="parenteral-leachable-thresholds-title">Nā paepae hiki ke hoʻoheheʻe makua</inoa> <wehewehe id="parenteral-leachable-thresholds-desc">Hoʻonohonoho ʻo PQRI i kahi 1.5 µg/lā ka paepae pilikia palekana a 5 µg/lā ka paepae hōʻoia no kēlā me kēia mea hoʻoheheʻe organik. Nā paepae hiki ke hoʻoheheʻe makua. ʻikepili lollipop: Pilikia palekana 1.5; Kuʻikahi 5. Puna: PQRI PODP Leachables & Pūʻulu Hana Nā mea hiki ke unuhi 2021-10-28.</wehewehe> <kikokikona x="280.0" y="29" heleuma kikokikona="waena" font-size="18" font-kaumaha="800" hoʻopiha="kala kala">Nā paepae hiki ke hoʻoheheʻe makua</kikokikona> <laina x1="145" y1="298.0" x2="510" y2="298.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="243.0" x2="510" y2="243.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="188.0" x2="510" y2="188.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="133.0" x2="510" y2="133.0" hahau ="kala kala" opacity="0.08" /> <laina x1="145" y1="78.0" x2="510" y2="78.0" hahau ="kala kala" opacity="0.08" /> <kikokikona x="136.0" y="137.0" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">Pilikia palekana</tspan></kikokikona> <laina x1="145" y1="133.0" x2="254.5" y2="133.0" hahau ="kala kala" opacity="0.15" kaha-ākea="1" /> <pōʻai cx="254.5" cy="133.0" r="6" hoʻopiha="#f97316" /> <kikokikona x="266.5" y="137.0" font-size="11" hoʻopiha="kala kala">1.5</kikokikona> <kikokikona x="136.0" y="247.0" heleuma kikokikona="hopena" font-size="11" hoʻopiha="kala kala" opacity="0.8"><puna x="136.0" dy="0">Kupono</tspan></kikokikona> <laina x1="145" y1="243.0" x2="510.0" y2="243.0" hahau ="kala kala" opacity="0.15" kaha-ākea="1" /> <pōʻai cx="510.0" cy="243.0" r="6" hoʻopiha="#38bdf8" /> <kikokikona x="522.0" y="247.0" font-size="11" hoʻopiha="kala kala">5</kikokikona> <kikokikona x="280.0" y="366" heleuma kikokikona="waena" font-size="10" hoʻopiha="kā mākou(--pakuhi-muted, kala kala)">Puna: PQRI PODP Leachables & Puʻupuʻu hana ʻo Extractable (2021-10-28)</kikokikona> </svg> </huahelu>

Noi ʻike, ka maemae, ʻike a me nā hōʻike kūpaʻa kūpono no ka peptide a me ka hōʻike hoʻopau. E koho i ka waiho ʻana a me nā kūlana i hoʻolalelale ʻia mai ka hoʻokumu ʻana, koi hoahu i manaoia a me ke alakai kupono; Q1A pahu hau(R2) ʻAʻole nā ​​kūlana he kikoʻī āpau no nā huahana peptide-device āpau.

Mai ka hoa pili, e noi i ka hoʻāʻo ʻana i ka ikaika injection a me ka hoʻāʻo ʻana i ka ʻai kūpono e kūʻē iā ISO 11608-1, e uhi ana i nā ʻōnaehana hoʻohana hoʻokahi i hoʻohana ʻia me ka syringe prefilled (ISO 11608-1:2022), ʻo ka pūʻolo hiki ke unuhi a me ka leachable, nā hopena kūpaʻa pani pani, a me ka hoʻāʻo ʻana i nā kumu kanaka autoinjector me nā mea hoʻohana ʻelele a me ka interface hope. ʻO ka FDA 2016 ʻO ke alakaʻi kumu kanaka e hoʻopuka i nā haʻawina kumu kanaka no nā huahana hui, e wehewehe ana i nā ʻano haʻawina a me nā ʻōlelo paipai no ko lākou manawa (ʻO ke alakaʻi alakaʻi ʻana i nā kumu kanaka FDA).

Mai mālama i ka bioequivalence wale nō ma ke ʻano he mākaukau o ka mea hana, mai laka i kahi paepae ma mua o ka kākau ʻia ʻana o ka loiloi pilikia pani pani, a mai heluhelu i ke kikoo alakai ma ke ano he koi. Ua hōʻike ʻia ka hana ʻoihana iā mākou, ʻaʻole i kākau ʻia ma ke alakaʻi, hoʻonohonoho i ka hoʻolālā mea hana ma ka pre-IND a i ʻole ka Phase mua 2 a me kahi kahua pāʻoihana ma ka hopena o ka Phase 2.

E noi i kāu hoa peptide no ka pūʻolo ʻikepili pae nui ma mua o kou laka ʻana i kahi ʻano hāmeʻa. Mea Hana Polypeptide

Pehea mākou e hoʻohana ai i kēia ma MOL Changes, ka mea hoʻopuka o kēia alakaʻi. Hāʻawi kā mākou peptide synthesis maʻamau i nā mea kikoʻī i ka maʻemaʻe i ʻōlelo ʻia, mai mg a i kg, me ka ho'āʻo HPLC a me MS, e uhi ana i ka ʻike a me ka ʻikepili maʻemaʻe āu e noi ai mai kahi hoa peptide. ʻAʻole ia e hoʻokumu i ka hana o ka mea hana, kūpaʻa i loko o ka pahu, a i ʻole ka ʻae hoʻoponopono; nā mea āu e hōʻoia mau nei me kāu hoa hana a me kāu mau haʻawina ponoʻī.

Nīnau pinepine

ʻO ka manaʻo o ka ZILBRYSQ autoinjector ka manaʻo e pono i kaʻu peptide kahi autoinjector?

ʻAʻole. Hoʻohui ka ʻae i kahi koho hoʻokele ma ka ʻaoʻao o ka syringe i hoʻopiha mua ʻia no hoʻokahi huahana i hoʻokahi hōʻailona (ʻO ka hoʻolaha ʻana o ka UCB). ʻO ka pono o kāu polokalamu e pili ana i ka nui o ka dose, viscosity a me ka heluna kanaka, ʻaʻole ma ka waiho ʻana o ka mea hoʻokūkū.

Ua lawa ka palapala hōʻoia no ke kākoʻo ʻana i ka hoʻouna ʻana i nā mea hana?

Kākoʻo ia i ka ʻāpana lāʻau-mea wale nō. ʻO kahi kikoʻī ma lalo o ICH Q6B e hōʻoia i ka maikaʻi a ʻaʻole i hōʻike i ka hana hoʻopuka, a me nā ʻāpana mea hana e lawe i nā manaʻolana ʻokoʻa no ka ikaika glide, ka ikaika hemo a me ka pono o ka sila (I Q6B).

Pehea e hoʻomaka ai ka hana ʻana o ka mīkini e pili ana i ka laka hana?

ʻAʻole hoʻokumu nā kumu i kahi kūlana manawa i kākau ʻia. ʻO ka mea a lākou e hōʻike ai, hiki i ka hoʻopili pahu ke hoʻololi i ka maikaʻi o ka huahana ma ka hoʻonohonoho paʻa, e like me ka hōʻike ʻana o ka epoetin alfa fill-volume, no laila aia ka loiloi pilikia pani pani ma mua o ka hoʻopaʻa ʻia ʻana ma mua o ka pau ʻana (Seidl et al.).

Pili anei ʻo ICH Q3E i kaʻu huahana hui i kēia lā?

E hoʻokaʻawale i ke kumu alakaʻi mai nā koi i ʻae ʻia. E nānā i ka ICH Q3E a me ke kūlana hoʻokō kūloko i ka wā e hoʻonohonoho ai i ka hoʻolālā extractables-and-leachables; ʻAʻole ka lā hoʻokō wānana he lā palena paʻa.

Ka hopena

ʻO ka ʻae ʻia ʻo ZILBRYSQ ʻoi aku ka maikaʻi o ka heluhelu ʻana ma ke ʻano he hōʻikeʻike i kahi e ola maoli ai nā hōʻike. ʻAʻole i loli ka mole; ka ipu, ua hana ka mea hoʻohana a me ka mea hoʻohana, a ʻo ka pūʻolo kākoʻo he bioequivalence, ka hoʻohana a me ka ʻikepili kumu kanaka ma mua o kahi kikoʻī maʻemaʻe hou.

Hoʻololi kēlā i ka mea a kahi hoa peptide aie iā ʻoe. Lot-specific ʻike a me ka maʻemaʻe, he pūʻolo kūpaʻa ma lalo o ICH Q1A(R2), a ʻo ka ʻōlelo maopopo o ka pH a me ka ʻōnaehana pale, he mau mea ia e hiki ai i ka hoa synthesis ke hāʻawi a ʻaʻole hiki i kahi hoa hana. Nā hualoaʻa hiki ke unuhi a me ka leachable, kūpaʻa pani pahu, ʻO nā ana ikaika a me ka hōʻoia ʻana i nā kumu kanaka no ka ʻaoʻao o ka mea hana, a ʻaʻohe palapala peptide e pani ai iā lākou.

ʻO ke kaʻina hana aʻe, ʻo ia ka palapala ʻana i kāu pūʻolo ʻikepili i kēia manawa e kūʻē i kēlā māhele ma mua o ka hoʻomaka ʻana o kahi kūkākūkā format. Ma kahi i piha ai ka ʻaoʻao peptide a nele ka ʻaoʻao, ʻike ʻoe i ke kamaʻilio ʻana ma hope, a me wai.

Hōʻike ka mea hoʻopuka: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a he hoihoi koʻikoʻi i kēia kumuhana. ʻO nā lālā lawelawe a me nā ʻōlelo hiki ke koi i nā mea hoʻolako; ʻO ka loaʻa a me ka hana ʻana no kahi kūkulu kikoʻī e koi i nā hōʻike kikoʻī o ka papahana.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana